Lundbeck to Acquire Abide Therapeutics for $400M

 Lundbeck to Acquire Abide Therapeutics for $400M

Lundbeck to Acquire Abide Therapeutics for $400M

Shots:

  • Lundbeck acquires Abide, in all-stock transaction for $400M. Abide to receive $250M upfront and $150M development & commercialization milestones with its expected closure in Q2’19
  • The focus of the acquisition is to strengthen Lundbeck’s CNS portfolio with the addition of Abide’s candidate (ABX-1431) and a chemo-proteomic platform for developing serine hydrolase inhibitors (SHs) to treat multiple CNS disorders
  • Abide’s ABX-1431 is a selective inhibitor of serine hydrolase monoacylglycerol lipase (MGLL), increasing endocannabinoid signaling to restore homeostatic balance in CNS and is evaluated in P-IIa & P-I for Tourette syndrome & neuropathic pain respectively

Click here to read full press release/ article | Ref: Lundbeck | Image: Lundbeck

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post